Drugs / TERN-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05415722 | Jun 2022 → Jul 2023 | metabolic dysfunction-associated steatohepatitis | Terns, Inc. | Completed | Met primary |
| Phase 2 | NCT04328077 | Jun 2020 → May 2021 | metabolic dysfunction-associated steatohepatitis | Terns, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TERN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04328077 ↗ |
| Known as | LY-2562175 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3746388 ↗ |
| Action | Activate | “TERN-101 (farnesoid X receptor agonist)” PMID 40500414 ↗ Jun 20251“Bile acid receptor FXR agonist” CHEMBL3746388 ↗ |
| Modality | Small molecule | — CHEMBL3746388 ↗ |
| Route | Oral | “Orally administered.” NCT04328077 ↗ |
| Target | NR1H4 | “Bile acid receptor FXR agonist” CHEMBL3746388 ↗ |